Pharmacokinetics of Carbenicillin through Different Dialysis Membranes

G, Naumann; Holtz, M; Müntner, W.; Nimmrich, W.; Budde, E; Klinkmann, H

doi:10.1007/978-1-4684-3123-0_15

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentrations of Bay K and mezlocillin in serum and urine were assayed by an agar diffu sion method (1.5°/o Difco Bacto nutrient agar, Difco, Detroit, Mich.) with Bacillus subtilis ATCC 6633 and Sarcina lutea ATCC 9344 as test orga nisms [20,21]. The special test performances were described in previous papers [15,16] …”

Section: A Ssaysmentioning

confidence: 99%

Clinical Pharmacology of a New Ureidopenicillin: Bay K 4999

Lode¹,

Tomas²,

Koeppe³

et al. 1980

Chemotherapy

View full text Add to dashboard Cite

A new semisynthetic ureidopenicillin (Bay K 4999) demonstrates favorably in vitro antibacterial efficacy against human-pathogenic gram-negative rods in comparison to mezlocillin and azlocillin. A comparative pharmacokinetic study was done with 10 test subjects after 30 min intravenous infusion of 4.0 g of Bay K and mezlocillin, respectively. The serum concentration course during a period of 10 h showed an open three-compartment model for both antibiotics. The urine recovery of Bay K 4999 during 24 h was only 32.6 ± 4.3% of the applied dose. In three test subjects with normal renal function, the average renal clearance of Bay K was 61.0, the total serum clearance was 409.2 ml/min/1.73 m². 31 patients were treated with a daily dose of 3 × 1.0–2.0 g Bay K for severe bronchopulmonary, UTI and cholangiogenic infections. The therapeutic results were good; the relatively high number of side effects should be further investigated in animal studies and require more clinical experience.

show abstract

Section: A Ssaysmentioning

confidence: 99%